Spexis provides business update and announces financial results for the full year 2022
May 30, 2023 01:15 ET
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR USD 4.5 million capital commitment from SPRIM Global Investments to enable initiation of ColiFin® COPILOT study; first patient dosing expected in...
Spexis announces closing of capital commitment of USD 4.5 million from SPRIM Global Investments (SGI) to enable initiation of ColiFin® Phase 3 study
April 18, 2023 02:23 ET
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR Funding to enable immediate initiation of the COPILOT study, the first of two Phase 3 ColiFin® studies; first-patient-in expected in June 2023Commitment...
Spexis and SPRIM Global Investments (SGI) Announce Plans for Clinical Trial Partnership to Fund up to Half of the Projected Phase 3 Clinical Development Costs of ColiFin®
February 08, 2023 02:00 ET
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR SGI debt facility to provide Spexis up to half of the projected ColiFin® Phase 3 development costs, including those involving both COPILOT and COPASGI...
Spexis reports solid safety and pharmacokinetics results from first-in-human study with inhaled murepavadin, a novel macrocycle compound
January 09, 2023 01:20 ET
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR Inhaled murepavadin shown to be well tolerated at all dose levels Program derived from Spexis’ macrocycle platformData support moving forward...
Spexis announces promising pre-clinical data with balixafortide in combination with various therapies on the market for treating B-cell lymphomas
December 13, 2022 01:32 ET
|
Spexis AG
Balixafortide shown to have synergistic or additive effect with conventional or targeted therapies across all tested B-cell lymphomas ALLSCHWIL, Switzerland, Dec. 13, 2022 (GLOBE NEWSWIRE) --...
Spexis announces positive renal impairment clinical trial results with balixafortide
September 22, 2022 01:20 ET
|
Spexis AG
Phase 1 clinical trial in patients with renal impairment demonstrates balixafortide to be safe and well tolerated Safety findings support potential to use significantly higher doses of balixafortide...
Spexis provides business update and announces financial results for the first half of 2022
September 06, 2022 01:20 ET
|
Spexis AG
Ad hoc announcement pursuant to Art. 53 LR Study start-up activities nearly complete for COPILOT, the first part of the Phase 3 ColiFin® program, including regulatory and ethics committee approvals...
Spexis announces presentation of half-year 2022 financial results and participation at upcoming industry and investor events in September
August 31, 2022 01:30 ET
|
Spexis AG
ALLSCHWIL, Switzerland, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX), a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company...
Spexis provides business update
July 28, 2022 01:20 ET
|
Spexis AG
Cash position to finance operations extended into January 2023Resources focused on advancing lead program, Phase 3 ColiFin®Assessment of balixafortide development options continues; balixafortide...
Spexis announces business update call to be held on July 28th
July 20, 2022 01:30 ET
|
Spexis AG
ALLSCHWIL, Switzerland, July 20, 2022 (GLOBE NEWSWIRE) -- Spexis AG (SIX: SPEX) a clinical-stage biopharmaceutical company focused on rare diseases and oncology, today announced that the Company...